Inhibiting the NADase CD38 improves cytomegalovirus-specific CD8+ T cell functionality and metabolism.

Autor: Mülling N; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Behr FM; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Heieis GA; Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Boss K; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., van Duikeren S; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van Haften FJ; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Pardieck IN; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van der Gracht ET; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Vleeshouwers W; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van der Sluis TC; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., de Graaf JF; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Veerkamp DM; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Franken KL; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Lei X; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van de Sand L; Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany., van der Burg SH; Department of Medical Oncology., Welters MJ; Department of Medical Oncology., Heidt S; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Huisman W; Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Jochems SP; Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Giera M; Center for Proteomics and Metabolomics, and., Witzke O; Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany., de Vries AP; Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands., Kribben A; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Everts B; Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Wilde B; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Arens R; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Jul 02; Vol. 134 (17). Date of Electronic Publication: 2024 Jul 02.

OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.

Autor: van der Sluis TC; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Beyrend G; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., van der Gracht ETI; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Abdelaal T; Department of Radiology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands; Systems and Biomedical Engineering Department, Faculty of Engineering, Cairo University, Giza 12613, Egypt; Pattern Recognition and Bioinformatics, Delft University of Technology, 2628XE Delft, the Netherlands., Jochems SP; Department of Parasitology, Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Belderbos RA; Department of Pulmonary Diseases, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands., Wesselink TH; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., van Duikeren S; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., van Haften FJ; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Redeker A; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Ouboter LF; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Beyranvand Nejad E; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Camps M; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Franken KLMC; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Linssen MM; Central Animal and Transgenic Facility, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Hohenstein P; Central Animal and Transgenic Facility, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Mei H; Department of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Bins AD; Department of Internal Medicine, Amsterdam University Medical Center, 1105AZ Amsterdam, the Netherlands., Haanen JBAG; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands., Aerts JG; Department of Pulmonary Diseases, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands., Ossendorp F; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Arens R; Department of Immunology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands. Electronic address: r.arens@lumc.nl.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 Mar 21; Vol. 4 (3), pp. 100939. Date of Electronic Publication: 2023 Feb 15.

Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells.

Autor: Duinkerken S; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., Li RE; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., van Haften FJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., de Gruijl TD; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Medical Oncology, Cancer Center Amsterdam, the Netherlands., Chiodo F; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., Schetters STT; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., van Kooyk Y; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands. Electronic address: y.vankooyk@amsterdamumc.nl.

Publikováno v: Current opinion in chemical biology [Curr Opin Chem Biol] 2019 Dec; Vol. 53, pp. 167-172. Date of Electronic Publication: 2019 Oct 31.